Zhu Hu, Roth Bryan L
Department of Pharmacology, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC (Drs Zhu and Roth).
Int J Neuropsychopharmacol. 2014 Oct 31;18(1):pyu007. doi: 10.1093/ijnp/pyu007.
Recently, we created a family of engineered G protein-coupled receptors (GPCRs) called DREADD (designer receptors exclusively activated by designer drugs) which can precisely control three major GPCR signaling pathways (Gq, Gi, and Gs). DREADD technology has been successfully applied in a variety of in vivo studies to control GPCR signaling, and here we describe recent advances of DREADD technology and discuss its potential application in drug discovery, gene therapy, and tissue engineering.
最近，我们创建了一类工程化的G蛋白偶联受体（GPCR），称为DREADD（仅由设计药物激活的设计受体），它可以精确控制三种主要的GPCR信号通路（Gq、Gi和Gs）。DREADD技术已成功应用于各种体内研究以控制GPCR信号传导，在此我们描述DREADD技术的最新进展，并讨论其在药物发现、基因治疗和组织工程中的潜在应用。
